Several direct and calculated biomarkers from the amyloid-β pool in blood are associated with an increased likelihood of suffering from mild cognitive impairment

Journal of Alzheimer's Disease

Volumn 36, Issue 1, 2013, Pages 211-219

  Pérez Grijalba, Virginia ^a   Pesini, Pedro ^a,b   Monleón, Inmaculada ^b   Boada, Mercè ^c,d   Tárraga, Lluís ^c   Ruiz Laza, Agustín ^c   Martinez Lagec, Pablo ^c   San José, Itziar ^b   Sarasa, Manuel ^a,b  

^a Araclon Biotech Ltd   (Spain)

^b Araclon Biotech   (Spain)

^c Inst Catala de Neurociencies Apl   (Spain)

^d HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

Aging; Alzheimer's disease; diagnosis; ELISA

Indexed keywords

AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; APOLIPOPROTEIN E4; CREATININE; SERUM ALBUMIN;

AGE; AGED; ALBUMIN BLOOD LEVEL; ALZHEIMER DISEASE; ARTICLE; BLOOD; BLOOD SAMPLING; BRAIN ATROPHY; CLINICAL ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIAGNOSIS RELATED GROUP; DISEASE ASSOCIATION; EDUCATIONAL STATUS; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENOTYPE; HEMATOCRIT; HUMAN; MALE; MILD COGNITIVE IMPAIRMENT; MINI MENTAL STATE EXAMINATION; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROTEIN ANALYSIS; RESTRICTION FRAGMENT; RISK FACTOR; SENSITIVITY AND SPECIFICITY; WECHSLER MEMORY SCALE;

EID: 84878842006     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-121744     Document Type: Article

References (62)

1. Nelson PT, Braak H, MarkesberyWR(2009) Neuropathology and cognitive impairment in Alzheimer disease: A complex but coherent relationship. J Neuropathol Exp Neurol 68, 1-14.
2. Fagan AM, Holtzman DM (2010) Cerebrospinal fluid biomarkers of Alzheimer's disease. Biomark Med 4, 51-63.
3. Sperling RA, Aisen PS, Beckett LA, Bennett DA, Craft S, Fagan AM, Iwatsubo T, Jack CR, Kaye J, Montine TJ, Park DC, Reiman EM, Rowe CC, Siemers E, Stern Y, Yaffe K, Carrillo MC, Thies B, Morrison-Bogorad M, Wagster MV, Phelps CH (2011) Toward defining the preclinical stages of Alzheimer's disease: Recommendations from the National Institute on Aging and the Alzheimer's Association workgroup. Alzheimers Dement 7, 280-292.
4. Aisen PS (2009) Alzheimer's disease therapeutic research: The path forward. Alzheimers Res Ther 1, 2.
5. Vellas B, Aisen PS, Sampaio C, Carrillo M, Scheltens P, Scherrer B, Frisoni GB, Weiner M, Schneider L, Gauthier S, Wied CC, Hendrix S, Feldman H, Cedarbaum J, Petersen R, Siemers E, Andrieu S, Prvulovic D, Touchon J, Hampel H (2011) Prevention trials in Alzheimer's disease: An EU-US task force report. Prog Neurobiol 95, 594-600.
6. Ewers M, Insel P, Jagust WJ, Shaw L, Trojanowski JJ, Aisen P, Petersen RC, Schuff N, Weiner MW (2012) CSF biomarker and PIB-PET-derived beta-amyloid signature predicts metabolic, gray matter, and cognitive changes in nondemented subjects. Cereb Cortex 22, 1993-2004.
7. Villemagne VL, Pike KE, Chetelat G, Ellis KA, Mulligan RS, Bourgeat P, Ackermann U, Jones G, Szoeke C, Salvado O, Martins R, O'Keefe G, Mathis CA, Klunk WE, Ames D, Masters CL, Rowe CC (2011) Longitudinal assessment of Abeta and cognition in aging and Alzheimer disease. Ann Neurol 69, 181-192.
8. Hampel H, Lista S, Khachaturian ZS (2012) Development of biomarkers to chart all Alzheimer's disease stages: The royal road to cutting the therapeutic Gordian Knot. Alzheimers Dement 8, 312-336.
9. Jack CR, Jr., Knopman DS, Jagust WJ, Shaw LM, Aisen PS, Weiner MW, Petersen RC, Trojanowski JQ (2010) Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol 9, 119-128.
10. Jack CR, Jr., Vemuri P, Wiste HJ, Weigand SD, Aisen PS, Trojanowski JQ, Shaw LM, Bernstein MA, Petersen RC, Weiner MW, Knopman DS (2011) Evidence for ordering of Alzheimer disease biomarkers. Arch Neurol 68, 1526-1535.
11. Shaw LM, Vanderstichele H, Knapik-Czajka M, Clark CM, Aisen PS, Petersen RC, Blennow K, Soares H, Simon A, Lewczuk P, Dean R, Siemers E, Potter W, Lee VM, Trojanowski JQ (2009) Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects. Ann Neurol 65, 403-413.
12. Fagan AM, Roe CM, Xiong C, Mintun MA, Morris JC, Holtzman DM (2007) Cerebrospinal fluid tau/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults. Arch Neurol 64, 343-349.
13. Stomrud E, Hansson O, Zetterberg H, Blennow K, Minthon L, Londos E (2010) Correlation of longitudinal cerebrospinal fluid biomarkers with cognitive decline in healthy older adults. Arch Neurol 67, 217-223.
14. Rolstad S, Berg AI, Bjerke M, Blennow K, Johansson B, Zetterberg H, Wallin A (2011) Amyloid-beta is associated with cognitive impairment in healthy elderly and subjective cognitive impairment. J Alzheimers Dis 26, 135-142.
15. Fagan AM, Mintun MA, Mach RH, Lee SY, Dence CS, Shah AR, LaRossa GN, Spinner ML, Klunk WE, Mathis CA, DeKosky ST, Morris JC, Holtzman DM (2006) Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans. Ann Neurol 59, 512-519.
16. Rowe CC, Ellis KA, Rimajova M, Bourgeat P, Pike KE, Jones G, Fripp J, Tochon-Danguy H, Morandeau L, O'Keefe G, Price R, Raniga P, Robins P, Acosta O, Lenzo N, Szoeke C, Salvado O, Head R, Martins R, Masters CL, Ames D, Villemagne VL (2010) Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging. Neurobiol Aging 31, 1275-1283.
17. Buchhave P, Minthon L, Zetterberg H, Wallin AK, Blennow K, Hansson O (2012) Cerebrospinal fluid levels of beta-Amyloid 1-42, but not of Tau, are fully changed already 5 to 10 years before the onset of Alzheimer dementia. Arch Gen Psychiatry 69, 98-106.
18. Graff-Radford NR, Crook JE, Lucas J, Boeve BF, Knopman DS, Ivnik RJ, Smith GE, Younkin LH, Petersen RC, Younkin SG (2007) Association of lowplasma Abeta42/Abeta40 ratios with increased imminent risk for mild cognitive impairment and Alzheimer disease. Arch Neurol 64, 354-362.
19. Schupf N, Tang MX, Fukuyama H, Manly J, Andrews H, Mehta P, Ravetch J, Mayeux R (2008) Peripheral A-subspecies as risk biomarkers of Alzheimer's disease. Proc Natl Acad Sci U S A 105, 14052-14057.
20. Blasko I, Jellinger K, Kemmler G, Krampla W, Jungwirth S, Wichart I, Tragl KH, Fischer P (2008) Conversion from cognitive health to mild cognitive impairment and Alzheimer's disease: Prediction by plasma amyloid beta 42, medial temporal lobe atrophy and homocysteine. Neurobiol Aging 29, 1-11.
21. Mehta PD, Pirttila T, Mehta SP, Sersen EA, Aisen PS, Wisniewski HM (2000) Plasma and cerebrospinal fluid levels of amyloid beta proteins 1-40 and 1-42 in Alzheimer disease. Arch Neurol 57, 100-105.
22. Mayeux R, Honig LS, Tang MX,Manly J, Stern Y, Schupf N, Mehta PD (2003) Plasma A-40 and A-42 and Alzheimer's disease: Relation to age, mortality, and risk. Neurology 61, 1185-1190.
23. Sundelof J, Giedraitis V, Irizarry MC, Sundstrom J, Ingelsson E, Ronnemaa E, Arnlov J, Gunnarsson MD, Hyman BT, Basun H, Ingelsson M, Lannfelt L, Kilander L (2008) Plasma beta amyloid and the risk of Alzheimer disease and dementia in elderly men: A prospective, population-based cohort study. Arch Neurol 65, 256-263.
24. Schupf N, Patel B, Pang D, Zigman WB, SilvermanW, Mehta PD, Mayeux R (2007) Elevated plasma beta-amyloid peptide Abeta(42) levels, incident dementia, and mortality in Down syndrome. Arch Neurol 64, 1007-1013.
25. Yaffe K, Weston A, Graff-Radford NR, Satterfield S, Simonsick EM, Younkin SG, Younkin LH, Kuller L, Ayonayon HN, Ding J, Harris TB (2011) Association of plasma beta-amyloid level and cognitive reserve with subsequent cognitive decline. JAMA 305, 261-266.
26. Toledo JB, Vanderstichele H, Figurski M, Aisen PS, Petersen RC, Weiner MW, Jack CR, Jr., Jagust W, Decarli C, Toga AW, Toledo E, Xie SX, Lee VM, Trojanowski JQ, Shaw LM (2011) Factors affecting Abeta plasma levels and their utility as biomarkers in ADNI. Acta Neuropathol 122, 401-413.
27. Hansson O, Stomrud E, Vanmechelen E, Ostling S, Gustafson DR, Zetterberg H, Blennow K, Skoog I (2012) Evaluation of plasma Abeta as predictor of Alzheimer's disease in older individuals without dementia: A population-based study. J Alzheimers Dis 28, 231-238.
28. Koyama A, Okereke OI, Yang T, Blacker D, Selkoe DJ, Grodstein F (2012) Plasma amyloid-beta as a predictor of dementia and cognitive decline:Asystematic reviewand meta-analysis. Arch Neurol 69, 824-831.
29. Lui JK, Laws SM, Li QX, Villemagne VL, Ames D, Brown B, Bush AI, De RK, Dromey J, Ellis KA, Faux NG, Foster J, Fowler C, Gupta V, Hudson P, Laughton K, Masters CL, Pertile K, Rembach A, Rimajova M, Rodrigues M, Rowe CC, Rumble R, Szoeke C, Taddei K, Taddei T, Trounson B, Ward V, Martins RN, AIBL Research Group (2010) Plasma amyloid-beta as a biomarker in Alzheimer's disease: The AIBL study of aging. J Alzheimers Dis 20, 1233-1242.
30. Pesini P, Pérez-Grijalva V, Monleón I, Boada M, Tárraga L, Martínez-Lage P, San-José I, Sarasa M (2012) Reliable measurements of the-amyloid pool in blood could help in the early diagnosis of AD. Int J Alzheimers Dis 2012, 604141.
31. Gabelle A, Richard F, Gutierrez LA, Schraen S, Delva F, Rouaud O, Buee L, Dartigues JF, Touchon J, Lambert JC, Berr C (2013) Plasma amyloid-beta levels and prognosis in incident dementia cases of the 3-City study. J Alzheimers Dis 33, 381-391.
32. Watt AD, Perez KA, Rembach AR, Masters CL, Villemagne VL, Barnham KJ (2012) Variability in blood-based amyloidbeta assays: The need for consensus on pre-analytical processing. J Alzheimers Dis 30, 323-326.
33. Lista S, Faltraco F, Hampel H (2013) Biological and methodical challenges of blood-based proteomics in the field of neurological research. Prog Neurobiol 101-102 18-34.
34. Rogers J, Li R, Mastroeni D, Grover A, Leonard B, Ahern G, Cao P, Kolody H, Vedders L, Kolb WP, Sabbagh M.(2006) Peripheral clearance of amyloid beta peptide by complement C3-dependent adherence to erythrocytes. Neurobiol Aging 27, 1733-1739.
35. Biere AL, Ostaszewski B, Stimson ER, Hyman BT, Maggio JE, Selkoe DJ (1996) Amyloid beta-peptide is transported on lipoproteins and albumin in human plasma. J Biol Chem 271, 32916-32922.
36. Costa M, Ortiz AM, Jorquera JI (2012) Therapeutic albumin binding to remove amyloid-beta. J Alzheimers Dis 29, 159-170.
37. Kuo YM, Emmerling MR, Lampert HC, Hempelman SR, Kokjohn TA, Woods AS, Cotter RJ, Roher AE (1999) High levels of circulating Abeta42 are sequestered by plasma proteins in Alzheimer's disease. Biochem Biophys Res Commun 257, 787-791.
38. Sagare AP, Deane R, Zetterberg H, Wallin A, Blennow K, Zlokovic BV (2011) Impaired lipoprotein receptormediated peripheral binding of plasma amyloid-beta is an early biomarker for mild cognitive impairment preceding Alzheimer's disease. J Alzheimers Dis 24, 25-34.
39. Kuo YM, Kokjohn TA, Kalback W, Luehrs D, Galasko DR, Chevallier N, Koo EH, Emmerling MR, Roher AE (2000) Amyloid-beta peptides interact with plasma proteins and erythrocytes: Implications for their quantitation in plasma. Biochem Biophys Res Commun 268, 750-756.
40. Alegret M, Boada-Rovira M, Vinyes-Junque G, Valero S, Espinosa A, Hernandez I, Modinos G, Rosende-Roca M, Mauleon A, Becker JT, Tarraga L (2009) Detection of visuoperceptual deficits in preclinical and mild Alzheimer's disease. J Clin Exp Neuropsychol 31, 860-867.
41. Alegret M, Espinosa A, Vinyes-Junque G, Valero S, Hernandez I, Tarraga L, Becker JT, Boada M (2012) Normative data of a brief neuropsychological battery for Spanish individuals older than 49. J Clin Exp Neuropsychol 34, 209-219.
42. Scheltens P, Leys D, Barkhof F, Huglo D, Weinstein HC, Vermersch P, Kuiper M, Steinling M, Wolters EC, Valk J (1992) Atrophy of medial temporal lobes on MRI in "probable" Alzheimer's disease and normal ageing: Diagnostic value and neuropsychological correlates. J Neurol Neurosurg Psychiatry 55, 967-972.
43. Hixson JE, Vernier DT (1990) Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with HhaI. J Lipid Res 31, 545-548.
44. Rissman RA, Trojanowski JQ, Shaw LM, Aisen PS (2012) Longitudinal plasma amyloid beta as a biomarker of Alzheimer's disease. J Neural Transm 119, 843-850.
45. Lambert JC, Schraen-Maschke S, Richard F, FievetN, Rouaud O, Berr C, Dartigues JF, Tzourio C, Alperovitch A, Buee L, Amouyel P (2009) Association of plasma amyloid beta with risk of dementia: The prospective Three-City Study. Neurology 73, 847-853.
46. Lewczuk P, Kornhuber J, Vanmechelen E, Peters O, Heuser I, Maier W, Jessen F, Burger K, Hampel H, Frolich L, Henn F, Falkai P, Ruther E, Jahn H, Luckhaus C, Perneczky R, Schmidtke K, Schroder J, Kessler H, Pantel J, Gertz HJ, Vanderstichele H, De MG, Shapiro F,Wolf S, Bibl M,Wiltfang J (2010) Amyloid beta peptides in plasma in early diagnosis of Alzheimer's disease: A multicenter study with multiplexing. Exp Neurol 223, 366-370.
47. Mattsson N, Portelius E, Rolstad S, Gustavsson M, Andreasson U, Stridsberg M, Wallin A, Blennow K, Zetterberg H (2012) Longitudinal cerebrospinal fluid biomarkers over four years in mild cognitive impairment. J Alzheimers Dis 29, 1-12.
48. Okereke OI, Xia W, Selkoe DJ, Grodstein F (2009) Ten-year change in plasma amyloid beta levels and late-life cognitive decline. Arch Neurol 66, 1247-1253.
49. Sagare A, Deane R, Bell RD, Johnson B, Hamm K, Pendu R, Marky A, Lenting PJ, Wu Z, Zarcone T, Goate A, Mayo K, Perlmutter D, Coma M, Zhong Z, Zlokovic BV (2007) Clearance of amyloid-beta by circulating lipoprotein receptors. Nat Med 13, 1029-1031.
50. Slemmon JR, Meredith J, Guss V, Andreasson U, Andreasen N, Zetterberg H, Blennow K (2012) Measurement of Abeta 1-42 in cerebrospinal fluid is influenced by matrix effects. J Neurochem 120, 325-333.
51. Sureshbabu N, Kirubagaran R, Jayakumar R (2009) Surfactant-induced conformational transition of amyloid beta-peptide. Eur Biophys J 38, 355-367.
52. Matsubara E, Sekijima Y, Tokuda T, Urakami K, Amari M, Shizuka-Ikeda M, Tomidokoro Y, Ikeda M, Kawarabayashi T, Harigaya Y, Ikeda S, Murakami T, Abe K, Otomo E, Hirai S, Frangione B, Ghiso J, Shoji M (2004) Soluble Abeta homeostasis in AD and DS: Impairment of anti-amyloidogenic protection by lipoproteins. Neurobiol Aging 25, 833-841.
53. Wolk DA, Price JC, Saxton JA, Snitz BE, James JA, Lopez OL, Aizenstein HJ, Cohen AD, Weissfeld LA, Mathis CA, Klunk WE, De-Kosky ST (2009) Amyloid imaging in mild cognitive impairment subtypes. Ann Neurol 65, 557-568.
54. Lopez OL, Kuller LH, Becker JT, Ulberg C, Weet RA, Ach HM, EKosky ST (2007) Incidence of dementia in mild cognitive impairment in the cardiovascular health study cognition study. Arch Neurol 64, 416-420.
55. Vemuri P,Wiste HJ,Weigand SD, Shaw LM, Trojanowski JQ, Weiner MW, Knopman DS, Petersen RC, Jack CR, Jr. (2009) MRI and CSF biomarkers in normal, MCI, and AD subjects: Predicting future clinical change. Neurology 73, 294-301.
56. Jagust WJ, Landau SM, Shaw LM, Trojanowski JQ, Koeppe RA, Reiman EM, Foster NL, Petersen RC,Weiner MW, Price JC, Mathis CA (2009) Relationships between biomarkers in aging and dementia. Neurology 73, 1193-1199.
57. Landau SM, Harvey D, Madison CM, Koeppe RA, Reiman EM, Foster NL, Weiner MW, Jagust WJ (2009) Associations between cognitive, functional, and FDG-PET measures of decline in AD and MCI. Neurobiol Aging 32, 1287-1218.
58. DeMeyer G, Shapiro F, Vanderstichele H, Vanmechelen E, Engelborghs S, De Deyn PP, Coart E, Hansson O, Minthon L, Zetterberg H, Blennow K, Shaw L, Trojanowski JQ (2010) Diagnosis-independent Alzheimer disease biomarker signature in cognitively normal elderly people. Arch Neurol 67, 949-956.
59. Jack CR, Jr., Vemuri P, Wiste HJ, Weigand SD, Lesnick TG, Lowe V, Kantarci K, Bernstein MA, Senjem ML, Gunter JL, Boeve BF, Trojanowski JQ, Shaw LM, Aisen PS,Weiner MW, Petersen RC, Knopman DS (2012) Shapes of the trajectories of 5 major biomarkers of Alzheimer disease. Arch Neurol 69, 856-867.
60. Devanand DP, Schupf N, SternY, Parsey R, Pelton GH, Mehta P, Mayeux R (2011) Plasma Abeta and PET PiB binding are inversely related in mild cognitive impairment. Neurology 77, 125-131.
61. Figurski MJ, Waligorska T, Toledo. J, Vanderstichele H, Korecka M, Lee VM, Trojanowski JQ, Shaw LM (2012) Improved protocol for measurement of plasma betaamyloid in longitudinal evaluation of Alzheimer's Disease Neuroimaging Initiative study patients. Alzheimers Dement 8, 250-260.
62. Bateman RJ, Xiong C, Benzinger TL, Fagan AM, Goate A, Fox NC, Marcus DS, Cairns NJ, Xie X, Blazey TM, Holtzman DM, Santacruz A, BucklesV, OliverA,Moulder K, Aisen PS, Ghetti B, Klunk WE, McDade E, Martins RN, Masters CL, Mayeux R, Ringman JM, Rossor MN, Schofield PR, Sperling RA, Salloway S, Morris JC (2012) Clinical and biomarker changes in Dominantly Inherited Alzheimer's Disease.NEngl J Med 367, 795-804.